CytoSorbents Corporation (CTSO)

[techxen]

Protection against ICH


This article was published today in the Journal of American College of Cariology. It outlines the use of dual anti-platelet therapy during cardiac surgery. However, the gains in ischemic protection afforded by DAPT are somewhat offset by increased risk of major bleeding by up to 30% to 70% and a serious complication which is intracranial hemorrhage (ICH). Fatality rates from ICH related to antiplatelet agents remain very high, at up to 60%. Cytosorb is mentioned in the article a strategy to reverse the antiplatelet effect of using oral P2Y12 inhibitors, and thus protection against ICH. Big unmet need.

https://www.jacc.org/doi/10.1016/j.jacc.2021.07.048